SFDA Closes Down Shanghai Hualian Pharmaceutical
This article was originally published in PharmAsia News
Executive Summary
China's State FDA has announced that it has revoked the drug production license and approval number of Shanghai Hualian Pharmaceutical. The company, a subsidiary of Shanghai Pharmaceutical Group, has been in the news recently for its adulterated methotrexate drugs which adversely affected some leukemia patients across China. Some of Shanghai Hualian's key products enjoy a 50 percent share of China's domestic market. Analysts note that SFDA's clamp down on a long-established national enterprise sends out strong signals and a warning to the drug manufacturing industry that the government will not compromise on food and drug safety. (Click here for more - Chinese Language)